Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Surgical Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1476593

Conversion therapy for unresectable intrahepatic cholangiocarcinoma using Gemcitabine plus S-1 combined with PD-1 inhibitors: a case report

Provisionally accepted
Shuangying Zhao Shuangying Zhao 1Xiaodong Zhang Xiaodong Zhang 1jialiang luo jialiang luo 2*kelei zhu kelei zhu 1*
  • 1 Department of Hepatopancreatobiliary Surgery, The Affiliated People’s Hospital of Ningbo University, Ningbo, China
  • 2 Ningbo University, Ningbo, Zhejiang Province, China

The final, formatted version of the article will be published soon.

    Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant tumor of the liver and gallbladder, which is usually diagnosed at an advanced stage and the opportunity for surgery is lost. Therefore, conversion therapy is important to convert the iCCA into a resectable state. In recent years, the conversion protocol of immuno-chemotherapy has been applied for advanced liver cancer. However, little has been reported about iCCA conversion therapy. The aim of this report is to present the results of conversion therapy with Gemcitabine plus S-1 (GS) combined with PD-1 inhibitors (Zimberelimab) in a 74-year-old female IIIB iCCA patient. After 6 cycles of conversion therapy, enhanced CT showed that the patient's tumor had shrunk to nearly half its original size, making radical resection possible. Postoperative pathology showed a complete pathological response. This provides a new way to convert advanced iCCA into resectable state.

    Keywords: intrahepatic cholangiocarcinoma, Conversion therapy, case report, immunotherapy combined therapy, PD-1

    Received: 06 Aug 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 Zhao, Zhang, luo and zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    jialiang luo, Ningbo University, Ningbo, 315211, Zhejiang Province, China
    kelei zhu, Department of Hepatopancreatobiliary Surgery, The Affiliated People’s Hospital of Ningbo University, Ningbo, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.